Literature DB >> 10229190

Role of the T cell receptor alpha chain in stabilizing TCR-superantigen-MHC class II complexes.

P S Andersen1, P M Lavoie, R P Sékaly, H Churchill, D M Kranz, P M Schlievert, K Karjalainen, R A Mariuzza.   

Abstract

Superantigens (SAGs) activate T cells by simultaneously binding the Vbeta domain of the TCR and MHC class II molecules on antigen-presenting cells. The preferential expression of certain Valpha regions among SAG-reactive T cells has suggested that the TCR alpha chain may modulate the level of activation through an interaction with MHC. We demonstrate that the TCR alpha chain is required for maximum stabilization of the TCR-SAG-MHC complex and that the alpha chain increases the half-life of the complex to match those of TCR-peptide/MHC complexes. The site on the TCR alpha chain responsible for these effects is CDR2. Thus, the overall stability of the TCR-SAG-MHC complex is determined by the combination of three distinct interactions: TCR-SAG, SAG-MHC, and MHC-TCR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229190     DOI: 10.1016/s1074-7613(00)80047-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  20 in total

1.  Comparison of the T cell patterns in leprous and cutaneous sarcoid granulomas. Presence of Valpha24-invariant natural killer T cells in T-cell-reactive leprosy together with a highly biased T cell receptor Valpha repertoire.

Authors:  M Mempel; B Flageul; F Suarez; C Ronet; L Dubertret; P Kourilsky; G Gachelin; P Musette
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition.

Authors:  Zarixia Zavala-Ruiz; Iwona Strug; Bruce D Walker; Philip J Norris; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-26       Impact factor: 11.205

3.  The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation.

Authors:  Maria Saline; Karin E J Rödström; Gerhard Fischer; Vladislav Yu Orekhov; B Göran Karlsson; Karin Lindkvist-Petersson
Journal:  Nat Commun       Date:  2010-11-16       Impact factor: 14.919

4.  Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1.

Authors:  Beenu Moza; Ashok K Varma; Rebecca A Buonpane; Penny Zhu; Christine A Herfst; Melissa J Nicholson; Anne-Kathrin Wilbuer; Nilufer P Seth; Kai W Wucherpfennig; John K McCormick; David M Kranz; Eric J Sundberg
Journal:  EMBO J       Date:  2007-02-01       Impact factor: 11.598

5.  Characterization of the Staphylococcal enterotoxin A: Vβ receptor interaction using human receptor fragments engineered for high affinity.

Authors:  P Sharma; S Postel; E J Sundberg; D M Kranz
Journal:  Protein Eng Des Sel       Date:  2013-10-27       Impact factor: 1.650

Review 6.  TCR recognition of peptide/MHC class II complexes and superantigens.

Authors:  Eric J Sundberg; Lu Deng; Roy A Mariuzza
Journal:  Semin Immunol       Date:  2007-06-07       Impact factor: 11.130

Review 7.  The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing.

Authors:  Peter Schuck; Huaying Zhao
Journal:  Methods Mol Biol       Date:  2010

8.  Measuring Protein Interactions by Optical Biosensors.

Authors:  Huaying Zhao; Lisa F Boyd; Peter Schuck
Journal:  Curr Protoc Protein Sci       Date:  2017-04-03

9.  Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis.

Authors:  Hong-Zhou Lu; Xin-Hua Weng; Bai Zhu; Haijing Li; You-Kuan Yin; Yong-Xin Zhang; David W Haas; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Skew in T cell receptor usage with polyclonal expansion in lesions of oral lichen planus without hepatitis C virus infection.

Authors:  A Gotoh; Y Hamada; N Shiobara; K Kumagai; K Seto; T Horikawa; R Suzuki
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.